Compare TRIN & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRIN | IMTX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | Germany |
| Employees | 109 | 407 |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | N/A |
| Metric | TRIN | IMTX |
|---|---|---|
| Price | $17.43 | $9.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $16.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 952.9K | 336.8K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 12.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.41 | N/A |
| Revenue Next Year | $10.00 | $25.91 |
| P/E Ratio | $7.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.13 | $5.05 |
| 52 Week High | $18.12 | $12.41 |
| Indicator | TRIN | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.64 | 42.05 |
| Support Level | $16.61 | N/A |
| Resistance Level | $18.10 | $10.67 |
| Average True Range (ATR) | 0.33 | 0.47 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 43.07 | 46.86 |
Trinity Capital Inc is an internally managed, closed-end, non-diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, capital appreciation through investments across five distinct vertical markets. The company is focused on achieving its investment objective by operating as a specialty lending company that provides debt, including loans, equipment financings, and asset-based lending, to growth-oriented companies, including institutional investor-backed companies. Its investment portfolio mainly comprises private companies that have begun to have success selling their products to the market and need additional capital to expand their operations and sales.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.